Predicting Kidney Failure, Cardiovascular Disease and Death in Advanced CKD Patients
Chava L. Ramspek(Parnassia Groep), Carin Wallquist(Skåne University Hospital), Anke Torp, Björn Rogland, Aleksandra Musiała, Rosemarijn Boekee(Leiden University Medical Center), Antonella De Blasio, Nicholas C Chesnaye(Amsterdam Neuroscience), Anna‐Lena Blom, Claudia Torino(Istituto di Fisiologia Clinica), Adamasco Cupisti(University of Pisa), Maarten G. Snoeijs(Maastricht University), Barbara McLaren, Andreas Jönsson, Christoph Wanner(Universitätsklinikum Würzburg), Magdalena Krajewska(Wrocław University of Science and Technology), Marie Evans(Karolinska University Hospital), Butti Alessandra, Alessandra Mele, Olof Heimbürger(Karolinska Institutet), Kitty J. Jager(Amsterdam University Medical Centers), Anna McKeever, Christiane Drechsler(Universitätsklinikum Würzburg), Andreas Schneider, Alex Còsaro, Andrea Ranghino, Joris I. Rotmans(Leiden University Medical Center), Gaetana Porto(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Asad Ullah, Adelia Sagliocca, Biagio Di Iorio(Ospedale Civile di Voghera), Boris Perras, Antonio Bellasi, Beate Iwig, Charlotte M Snead(University of Bristol), Anita Schrander, Alistair Woodman, Maciej Szymczak(Wroclaw Medical University), Alberto Ferraro, Andrea Stucchi(Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo), Friedo W. Dekker(Leiden University Medical Center), Alessandro Naticchia(Agostino Gemelli University Polyclinic), Fergus Caskey, Bastiaan van Dam(Noordwest Ziekenhuisgroep), Antonello Pani, Angelo Pignataro, Camille Harron, Aris Tsalouichos, Merel van Diepen(Leiden University Medical Center)
Cited by 18
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886
An introduction to inverse probability of treatment weighting in observational research
|Clinical Kidney Journal|2021|877